Background: In addition to lowering lipids, statins also may be beneficial for older adults sustaining a traumatic brain injury (TBI), as statin use prior to and following trauma may decrease mortality following injury. However, despite statins' potential to reduce mortality, there is limited research regarding statin use among older adults. Objective: To characterize and investigate factors associated with statin use among older adults with TBI. Methods: A retrospective drug utilization study was used to characterize statin use among Medicare beneficiaries 65 and older hospitalized with a TBI during 2006 to 2010 and with continuous Medicare Parts A, B, and D coverage 6 months prior and 12 months following TBI. Logistic regression was used to investigate the factors associated with statin use. The exposure of interest was statin use prior to and following TBI. Results: Of the 75 698 beneficiaries included in the study, 37 874 (~50%) of beneficiaries used a statin at least once during the study period. The most common statin used was simvastatin, while fluvastatin was the least used statin. Statin users were more likely to have cardiovascular diseases when compared to nonusers. Hyperlipidemia was a major factor associated with statin use and had the greatest impact on statin use compared to nonuse (odds ratio = 9.54; 95% confidence interval = 9.07, 10.03). Conclusions: This national sample of older adults with TBI suggests that statins are commonly used. Future studies must next examine the impact of statin use on mortality and secondary injury in order to shape pharmacological therapy guidelines following TBI.
Introduction
There are approximately 200 million statin users worldwide, 30 million of whom live in the United States. 1 Statins are Food and Drug Administration-approved therapy for the treatment of hyperlipidemia and are used for the primary and secondary prevention of cardiovascular events among older adults (defined as adults aged 65 or older) with cardiovascular disease (CVD). [2] [3] [4] [5] While the lipid lowering effects of statin therapy for older adults with and without CVD is established, 2, 3 it has been suggested that statins also may be beneficial for older adults sustaining a traumatic brain injury (TBI). 6, 7 Among older adults, TBI is associated with increased mortality and decreased life expectancy. 8, 9 Older patients with TBI also frequently experience secondary injury following TBI, such as stroke, neurological disorders, and mood disorders. 9 Currently, there is no ideal pharmacological treatment for older adults with TBI, as most treatments are for symptoms of secondary injury occurring after TBI. 10 However, statin use prior to trauma may decrease inhospital mortality in the elderly following injury. 11, 12 Additionally, statin use following TBI also has been suggested to decrease secondary injury, possibly due to statins' anti-inflammatory properties. [13] [14] [15] Statins' anti-inflammatory properties may help decrease mortality following TBI because TBI is characterized by inflammation, which can cause death and secondary injury.
Despite statins' potential to reduce in-hospital mortality if taken prior to TBI and their promise as an option for the pharmacological treatment following TBI in older adults, 14, 15 there is limited research regarding statin use among older adults. Among elderly Medicare beneficiaries, the implementation of the Medicare Part D drug benefit program has increased the use of statins; however, statin use remains suboptimal among many patients with CVD or recovering from cardiovascular events. [16] [17] [18] With regard to TBI, only a few observational studies have examined statin use in trauma patients; of these, 3 studies assessed statin use prior to trauma 11, 12, 19 and a fourth assessed statin continuation following trauma. 20 Another study examined the impact of hyperlipidemia on depression following TBI, in which secondary analyses examined the role of statins. 21 Regardless, these studies were limited due to small sample sizes and poor identification of statin use, as the statin used was not specified. Furthermore, none of these studies assessed persistence and factors associated with statin use. Last, these studies did not seek to characterize statin use prior to and following TBI; rather, they sought to examine the beneficial impact of statin therapy on trauma.
Given the potential protective effect statins may have in older patients with TBI, it is important to understand the extent of statin use in this population. Yet the data are relatively scant despite myriad data on statins. Therefore, it is important to characterize the extent of statin use in older adults with TBI prior to examining the potential beneficial impact of statins on in-hospital mortality and secondary injury following TBI; this study would provide important information that will lay the foundation for studies examining their protective effect. The objective of this study is to characterize statin use before and after TBI in a nationally representative sample of older Medicare beneficiaries and to identify the factors associated with that use.
Methods

Data and Sample
This study used Medicare administrative claims data from the Centers for Medicare and Medicaid Services. These data include all Medicare beneficiaries 65 years and older who suffered a TBI between 2006 and 2010. TBI was defined using International Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM], codes 800. xx, 801.xx, 803.xx, 804.xx, 850.xx-854.1x, 950.1-950.3, and 959.01 in any position. These codes have been used in prior research, and the Centers of Disease Control and Prevention also defines adult head trauma using these codes. 22, 23 Beneficiaries' first admission date for TBI during this time period was defined as the index date/TBI. TBIs occurring within 14 days of a previous TBI were collapsed and classified as a single TBI event due to the likelihood that multiple TBI claims within 14 days are for care of a single TBI event. Beneficiaries were required to have Medicare Parts A, B, and D coverage 6 months prior to TBI and 12 months following TBI. Beneficiaries with Medicare Part C coverage were excluded because prescription drug claims were not available for those beneficiaries.
Measures
The exposure of interest for this drug utilization study was statin use. Statins included in the study were atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. Combination drugs that contained a statin were classified as that individual statin; for instance, beneficiaries using ezetimibe/simvastatin were classified as using simvastatin. Exposure to statins was determined using Medicare Part D prescription drug claims. Statin use was examined per 30-day period relative to the index TBI. Prescription fills and proportion of days covered (PDC) were used to measure statin use in a 30-day period. PDC was calculated by dividing the number of days the drug is available (days of use covered per prescriptions filled) by the total number of days in a specified time period (30 days). 24 Beneficiaries were flagged as having statin use in a period if there was a fill for a statin in the period or a PDC greater than zero. Both prescriptions filled and PDC information were used to classify statin use because of the possibility of single prescription fills of greater than 30 days' supply will cause beneficiaries to have a prescription filled in only one period, with a PDC lasting 3 periods. 25 There was no washout period for statin use as the purpose of this study was to examine any statin use rather than just new use of statins. Future studies examining outcomes following TBI may consider including new users to reduce bias associated with prevalent users.
Beneficiaries had 6 periods of coverage to examine exposure prior to the index TBI and 12 periods of coverage to examine exposure following the index TBI. Therefore, proportion of statin use by drug class and individual statins was calculated per 30-day period 6 periods prior to and 12 periods following TBI. Average duration of use and average number of and duration of gaps among statin users were calculated. A gap in use was defined as a period without a prescription fill of a statin and a PDC of 0. Average statin dose per 30-day period also was calculated for individual statins.
Covariates examined included demographic characteristics (age, race, and sex), and chronic conditions associated with CVD (hypertension, hyperlipidemia, ischemic heart disease [IHD], congestive heart failure [CHF], acute myocardial infarction [AMI] , valvular heart disease [VHD] , and history of stroke/transient ischemic attack [TIA] ). Additional covariates were Alzheimer's disease and related dementias, diabetes, and a count of Centers for Medicare and Medicaid Services' chronic condition data warehouse chronic conditions, excluding the above-mentioned cardiovascular and chronic conditions (Appendix A). Beneficiaries were flagged for a comorbidity if it was present at the time of TBI. Last, covariates associated with injury severity, including length of hospital stay and independent survival risk ratio were examined. Independent survival risk ratio is part of the ICD-9 injury severity score, which is used to assess injury severity based on ICD-9 diagnosis codes. 26 Measures of injury severity based on ICD-9 codes have demonstrated to be valuable in administrative claims research. 27 It should be noted that injury severity covariates were only examined for beneficiaries that used statins only following TBI as injury severity cannot predict statin use prior to injury.
Statistical Analysis
Associations with covariates between statin users and nonusers were tested using χ 2 test for categorical variables and Student's t tests for continuous variables. Additionally, the Wilcoxon rank sum test was used to test differences between 2 medians. Logistic regression was used to identify factors associated with any statin use. Statin use was first categorized as use or nonuse, and then as no use, less than or equal to 50% use throughout study period, and greater than 50% use throughout study period. Additional sensitivity analyses was conducted by stratifying factors associated with statin use among beneficiaries that only used statins prior to TBI and beneficiaries that only used statins following TBI. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported.
All analyses were performed with SAS version 9.2 (Cary, NC). This study was approved by the University of Maryland Baltimore Institutional Review Board.
Results
A total of 116 170 Medicare beneficiaries 65 years and older without Medicare Part C were hospitalized with a TBI during 2006 to 2010. Of these beneficiaries, 83 461 had continuous Medicare Parts A, B, and D coverage 6 months prior to TBI. The final sample included 75 698 beneficiaries that also had continuous Medicare Parts A, B, and D coverage 12 months following TBI. Of the 75 698 beneficiaries in the study sample, 37 874 (50%) used at least one statin during the study period.
The study population was predominately white (87%) and female (67%). The mean age of statin users was less than that of nonusers (81.3 years compared with 83.3 years, P < .001). Statin users were more likely to have a diagnosis of hyperlipidemia recorded when compared with nonusers (94% vs 59%, P < .001). Furthermore, statin users also were more likely to have CVD, including AMI, IHD, CHF, and VHD (all P < .001). Additionally, while statistically different, there were very little differences between length of hospital stay and TBI severity among statin users and nonusers (Table 1) .
Of the 37 874 statin users, there were 30 378 (80%) beneficiaries who used statins prior to and following TBI; 1969 (5%) only used statins prior to TBI and 5527 (15%) used statins only following TBI. Among statin users, the average duration of use was 12.4 months. There were 14 475 (38.2%) users with at least one gap in use. Among these users, the average number of gaps was 1.5 and the average gap duration was 3.3 months ( Table 2) . Figure 1 illustrates trends in statin use throughout the study period and the dip associated with TBI hospitalization (a period when statin use would not be recorded by Medicare Part D claims). Statin use per 30-day period ranged from 35% to 40%, prior to and following TBI with no sudden increase postdischarge. There is a significant drop in statin use around the TBI, potentially causing gaps in statin use. The most common statin used was simvastatin, followed by atorvastatin. Fluvastatin was the least used statin, with approximately 1% of the sample using fluvastatin per 30-day period throughout the study duration. The average dose of statins per 30-day period fluctuated 1 mg to 4 mg throughout the study duration (Appendix B).
When comparing any statin use to nonuse, increasing age was associated with decreased use (OR = 0.52; 95% CI = 0.50, 0.55, for beneficiaries 85 years or older, compared with beneficiaries aged 65-75 years). Additionally, female sex was associated with lower odds of using statins (OR = 0.91; 95% CI = 0.88, 0.94) than males. Among chronic conditions, hyperlipidemia had the greatest association with statin use (OR = 9.54; 95% CI = 9.07, 10.03). Hypertension, IHD, AMI, VHD, diabetes, and prior stroke/TIA also were significantly associated with statin use (Table 3) . Logistic regression comparing less than 50% statin use to no use, and comparing greater than 50% statin use to no use showed similar associations (Table 3) .
Sensitivity analyses among beneficiaries with statin use only prior to TBI indicated similar results as the primary analysis. However, when examining beneficiaries who only used statins following TBI, the association with hyperlipidemia lessened when compared with the primary analysis for beneficiaries that used statins prior to and following TBI. While still a significant factor associated with statin use, the OR for hyperlipidemia was 2.39 (95% CI = 2.22, 2.53), comparing any statin use to no use; 2.27 (95% CI = 2.04, 2.53) comparing 50% use to no use; and 2.48 
Discussion
This national sample of older adults with TBI suggests that statins are commonly used. Among the 75 698 beneficiaries in the study sample, approximately 50% of beneficiaries (37 874) used statins at some point during the study period. The data suggest that among users, the average statin use duration was 12.4 months (69% of study period), and users had an average of 0.9 gaps in statin treatment. Of statin users, 85% (32 347) of beneficiaries used statins prior to TBI. Of these, 6% (1969) of beneficiaries who used statins prior to TBI stopped using statins following injury, suggesting that most statin users continued statin therapy following TBI. The 3 observational studies that assessed statin use prior to trauma found that 20% to 22% of the participants took statins prior to injury. 11, 12, 19 It should be noted that one study examining pretrauma statin use did not limit their study population to older adults and included all trauma patients. 11 One study that assessed statin continuation following trauma found that among adults 55 years or older, approximately 50% continued to receive statins during trauma hospitalization. 20 Our results suggest greater statin use prior to injury among older Medicare beneficiaries with TBI. This may be because our study includes Medicare beneficiaries with Medicare Part D and availability of prescription drug insurance is associated with statin use. 28 The previous studies did not examine the drug insurance status of trauma patients. Nonetheless, no previous study has examined trends in statin utilization prior to and following TBI.
Findings indicate that 76% of the study population had hyperlipidemia, of which 62% (35 667) used statins at some point in the study period. Previous research utilizing National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey suggests that 41% of participants with hyperlipidemia use statins. 29 Furthermore, previous research also has indicated that two thirds of patients with CVD or CVD risk factors take statins. 30 The biggest factor associated with statin use was hyperlipidemia. Comparing any statin use to nonuse, beneficiaries with hyperlipidemia were 9 times more likely to take statins. When comparing statin use for greater than 50% of the study period to no use, beneficiaries with hyperlipidemia were more than 13 times more likely to use statins. CVD such as IHD and AMI also were significantly associated with statins. These data support previous research indicating that hyperlipidemia and CVD are major factors associated with statin use. 29 However, no previous study has examined factors associated with statin use in an older Medicare population with TBI.
Among beneficiaries that only used statins following TBI (n = 5527), beneficiaries with hyperlipidemia were approximately 2.5 times more likely to use statins. The low impact of hyperlipidemia among beneficiaries that only took statins following TBI, when compared with beneficiaries that took statins prior to and following TBI, may suggest that beneficiaries may have been prescribed statins following injury in order to protect against adverse events associated with TBI rather than for hyperlipidemia. It is also possible that clinicians encouraged statin use among beneficiaries that were hospitalized with CVD, as this may have presented an opportunity to start statin therapy. Unfortunately, drug prescribing indication is not available in the data. While this is the first study to examine statin use in older Medicare beneficiaries with TBI, there are limitations to this study. First, medications taken during TBI hospitalizations are not captured in the data. This is because medication use during hospitalization is covered under inpatient coverage (Medicare Part A) rather than prescription drug coverage (Medicare Part D). Furthermore, this study uses prescription fill and PDC information to assess statin use. However, given the data, it is not possible to assess statin consumption by beneficiaries. Additionally, the indication for statin use cannot be assessed in these data. Indications of statin use can help in better understanding the factors associated with statin use. Another limitation of the study is that this study excluded beneficiaries with Medicare Part C because their prescription drug information was not available; thus, study findings are only generalizable to Medicare beneficiaries with fee-for-service coverage.
Strengths of this study include a large sample of older Medicare beneficiaries with TBI. This large sample allowed researchers to assess statin utilization by class and by individual statins. This is the first study to examine statin dose changes over time in older adults with TBI. Another strength of this study is that statin use both prior to and following TBI was examined. This allowed researchers to examine average duration and gaps in statin use prior to and following TBI among adults 65 and older.
Results of this study provide valuable information regarding statin use in a vulnerable population of older adults with TBI. The current study indicated that more than 76% of the study sample has hyperlipidemia; however, 50% of the sample took statins. Additionally, 15% of users started statin therapy following TBI, which may potentially have been given to reduce secondary injury following TBI. Given the potential protective impact of statins in reducing primary and secondary injury, clinicians can look to prescribe and encourage statin use among vulnerable older adults. Clinicians also can look to prescribe statins to patients with a history of or risk of TBI among older adults aged 65 and older. While this study provides understanding on the extent of statin use, future studies must next examine the impact of statin use on mortality and secondary injury in order to shape pharmacological therapy guidelines following TBI. 
Appendix A
Appendix C
Sensitivity Analysis
Factors associated with statin use only prior to TBI (Table C.1) and only post-TBI (Table C. 2). 
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